The aim of this manuscript is to provide insights into the theoretical and practical foundations of high intensity focused ultrasound (HIFU), a novel minimally invasive treatment option for benign prostatic hyperplasia (BPH). We therefore briefly review the physics of HIFU, the results of experimental studies, the histological impact of HIFU on the human prostate and clinical data so far available with this new technique. Key words: benign prostatic hyperplasia -high intensity focused ultrasound -minimally invasive therapy -prostatic cancer.
Physics of high intensity focused ultrasound (HIFU)
Ultrasound waves focused by a transducer and emitted at high energy are capable of generating 80-100°C at the focal point, where this intense heat results in coagulative necrosis (1, 2) . The characteristics of the beam, its size, the size of the focal zone, and the amount of energy delivered are functions of the characteristics of the transducer and the power supply driving the transducer. For experimental animal studies and human trials, the energy at the focus is set in the range of 10 3-104 watts (W)/ ern-and therefore exceeds that of conventional ultrasonography by the factor 10 4 • The focal area is very distinct, comprising only a few millimetres. This focal zone is moved by transducer movement in the sheath under computer control to create an adequate lesion volume. By focusing the ultrasound waves, thermolesions of intervening and adjacent tissue segments are prevented. Therefore HIFU offers the unique means of inducing contact -and irradiation -free coagulative necrosis in any solid organ accessible to ultrasound.
Experimental studies
The technique of HIFU has been tested in various experimental settings, such as tumours of the central nervous system and the liver, as well as canine prostates (2;3) . In all these studies, coagulative necrosis was identified in the treated tissue segments. Recently, Foster et al. extensively studied the histological effect of transrectal HIFU on 26 canine prostates which were sacrificed between a time interval of 2 hours up to 12 weeks following HIFU (3) . Within the first 72 hours post HIFU, the treated areas appeared as dark brownish black lesions on gross pathology. After 14 days, early formation of cystic cavities were identified and after 3 months these intraprostatic cystic cavities were consistently present, lined with urothelium and connected with the urethra via ducts. In all animals, surrounding structures such as the rectal wall and the prostate capsule were invariably intact.
These canine studies clearly proved the feasibility, safety and efficacy of transrectal HIFU in inducing contact-free intraprostatic coagulative necrosis via the transrectal approach and were the basis for the initiation of phase IIII human trials.
HIFU-treatment for human BPH
For treating human BPH, the transrectal approach appears appropriate because of the anatomical vicinity of rectum and prostate, which facilitates HIFU-treatment from the technical standpoint. By using the transabdominal approach, Vallancien et al. were unable to identify the prostate accurately enough for HIFU-treatment in approx. 50% of cases (4) . In addition, the symphysis shields the prostate thus making it inaccessible for HIFU. Finally, the long focal length necessary for the transabdominal approach requires the use of higher energy levels increasing the potential risk of damaging intervening tissues (4). To date, the clinical efficacy of transrectal HIFU for BPH has only been reported using the Sonablate device (Focus Surgery Inc., Milpitas, USA) and thisarticle therefore refers only to this particular apparatus (5-9) ( Fig. 1 ). Fig. 1 The transrectal HIFU-system (Sonablate). The transrectal HIFU-transducer, capable of both diagnostic imaging and therapeutic HIFU, is indicated by the arrow. With the aid of the computer unit on the left side, the HIFU-target area is defined and the HIFU-procedure is monitored on-line.
The ultrasound transducer is a piezoceramic element, operates with a 4.0 MHz wavelength and is capable of both diagnostic imaging and HIFUtreatment. The patient is placed in the classic lithotomy position. A 16 French transurethral A. PYCHA E ALTRI balloon catheter is inserted to allow exact identification of urethra, bladder neck and veru montanum during the imaging phase. The HIFU-transducer is lubricated with gel and inserted into the rectum. The condom covering the sheath is inflated with approx. 30cc of degassed water for exact airfree coupling of HIFU to tissue. Subsequently, the transducer is moved to an appropriate position in relation to the prostate under direct ultrasound guidance. Once the optimal position is obtained, the transducer is fixed to the operating table with a locking arm device. The image is displayed on the computer screen. The longitudinal extension of the treatment zone along the urethra is defined individually by the surgeon using a track ball on the computer keyboard. The treatment is started after the transurethral catheter is removed. The attenuation of canine and human rectal wall in the prostate are comparable and assumed to be 0.7 db/mHz/em. Based on canine experiments the power at the focal point was set at 1680 W /crn-. After the initial zone has been treated in the 12 o'clock position, the transducer rotates laterally and creates another zone in the far lateral aspect of the transverse plane. Ultimately nine sectors are subjected to therapy in the transverse plane. Once HIFU-therapy is completed, the condom is deflated and the transducer is removed from the rectum.
Histological impact of HIFU on the human prostate
A total number of 22 human prostates were treated at our institute in vivo with HIFU (Sonablate, Focus Surgery Inc., CA, USA) prior to surgical removal (5, 7) . Prostatectomies were performed for BPH (n = 4; suprapubic prostatectomy; time interval between HIFU and surgical removal: 30 min.), localised prostate cancer (n =12; radical prostatectomy; time interval between HIFU and surgical removal: 2-3 hrs) and invasive bladder cancer (n =6; radical cystoprostatectomy; time interval between HIFU and surgical removal: 6-10 days). After surgery, samples were fixed in formalin and then analysed using light and electron microscopy (7) .
Thermolesions in good correlation with the computer-defined segment were identified in all HIFV is a safe and effective means of inducing intraprostatic coagulative necrosis with a predictable location and size.
Clinical results of transrectal HIFU for BPH xx: p < 0.001 Fig. 3 AUA-symptom score before after transrectal HIFU. The AUA-score showed a statistically highly significant improvement after HIFU. To date, world-wide, approximately 250 BPHpatients have been treated with transrectal HIFV in an international phase II-clinicaltrial. We report the published clinical results (5, 6, 8, 9) . Inclusion/exclusion criteria were uniform, i.e.: Qmax< 15 milsec; AVA symptom score> 18, prostate volume < 75 ml and a prostate specificantigen (PSA)< 10 ng/ml. Post-HIFV, patients were followed at regular time intervals on an outpatient basis (including AVA symptom score, uroflow, residual volume, transrectal ultrasonography, serum PSA).
At our institute so far we have treated 86 patients and we report the clinical results of the first 50 patients (5, 9) . The total treatment time lasted for a mean of 44.7:±:16.1 min., including both the diagnostic and therapeutic part. Predictably, serum PSA rose from 2.05 :±:2.7 ng/ml to 11.2:±:8.5 ng/ml within 24 hrs post HIFV and returned to baseline within 4-6 weeks. All other laboratory parameters remained without statistically significant changes throughout the observation period. Significant clinical improvements were observed both in the subjective (AVA-score; Fig. 3 ) and ob- specimens (n = 22) ( Fig. 2) . When lesions were still fresh (max 3 hrs after HIFV) they could only be identified microscopically: epithelial cells showed small, pycnotic and heavily discoloured nuclei. The surrounding cytoplasm was small and irregularly vacuolated. Cells were detached from the basal membrane, cell-to-cell contacts were disrupted, and the interstitial connective tissue revealed massive oedematous alterations. Within 5-7 days post-HIFV, the treated tissue segments presented as typical macroscopic coagulative necrosis. The line between viable and necrotic tissue was very sharp, comprising only 5-7 cell layers.
Electron microscopy revealed massive alterations at cellular level, including destruction of the cell organelles and ruptured membranes. These changes are considered a positive sign of definitivecelldeath (point of no return) (7) .
The extent of histologically evident coagulative necrosis was correlated to the computer defined tissue segment to be treated (5) . The mean calculated treatment volume was 1.2:±:0.3 ml (mean:±:SD). Histology revealed a mean lesion size of 2.7:±:1.3 ml (n =22). When analysing the three axes of the HIFV treated tissue zone separate-Iy, the mean differences between calculated and histologically evident lesion were + 49:±: 36%, + 2 :±: 22 % and + 16 :±: 4 % in the sagittal, transverse and cranio-caudal dimension, respectively.
These data clearly demonstrate that transrectal 
Discussion
A. PYCHA E ALTRI nography (7.5 MHz) in approx. 25% of patients. These cavities appear as early as 6 weeks after HIFU and are still present 1 year after HIFU. Overall, HIFU-treatment was well tolerated, with a mean hospitalisation period of 1.1 days. The first ten patients underwent a rectoscopy immediately after the procedure, which yielded normal results in all patients. None of the patients had postoperative complaints in the anal region. The predominant side effect, observed in almost all patients, was urinary retention. A 10 French cystostomy catheter was therefore routinely placed intraoperatively, which could be removed on an outpatient basis after a mean of 6 days. The majority of sexually active patients reported a hematospermia, whichdisappeared spontaneously after 4-6 weeks. , Bihrle et aI. recently reported the initial U.S. experience of 15 patients and noticed after 3 months an increase of the Qmax from 9.3 milsec to 14.0 mil sec; within the same time period, the AUAsymptom score decreased from 31.2 to 15.8 (6) . Ebert et aI. treated a total number of 22 patients, 8 of whom were in urinary retention, and reported similar results, i.e. an improvement of the Qmax from 6.1 milsec to 14.1 mil sec, and a decrease of the IPSS form 16 to 8.5 and of the post void residual volume from preoperative 165 ml to 46 ml after 3 months (8).
".,4 jective (uroflow, residual volume; Fig. 4,5 ) BPHparameters. After 12 months (n = 30), the Qmax had improved by 47% and the subjectivesymptoms were reduced by a mean of 55%. More than a 50% reduction of the AUA-symptom score was noticed in 77% of all patients. In our series, eight out of the 50 patients treated had suffered from recurrent urinary retention preoperatively with the need of a catheter at the time of surgery. After HIFUtreatment, all of these patients were again able to urinate spontaneously, with a post-void residual volume of less than 100 mI.
Intraprostatic cystic cavities, comparable to post TUR/P, were demonstrable by transrectal ultraso-The main objective of the above-mentioned studies was to establish the feasibility, safety and efficacyof thermoablation of the prostate by HIFU. The histological data (see Fig. 2 ) clearly demonstrate that this technique is capable of destroying human prostatic tissue while preserving intervening tissue, such as the rectal mucosa and the posterior prostate capsule. Hence the greatest advantage of" HIFU over other currently tested minimally invasive treatment options for "BPH (transurethral microwave thermotherapy, side firing laser technique) is that the treatment is contactfree (10) (11) (12) (13) (14) . It thereby becomes possible to selectively coagulate periurethral tissue segments through the transrectal route while avoiding the side effects and risks associated with urethral manipulation.
As the clinical experience with this new technique is still limited, a conclusion about its future role as a minimally invasive treatment option for BPH cannot be definitely drawn at the present time. However, clinical data of phase-Il-clinical trials so far available, including long-term clinical experience (12 months) at our institute, allow some conclusions (5, 6, 8, 9) .
1. HIFU-treatment for BPH is associated with very little post-operative morbidity: the therapy is blood-free; patients reported no anal discomfort and particularly post-operative dysuria is minimal.
2. The therapeutic effect is greater than that of microwave thermotherapy and is in the range of what has been reported for various lasertechniques.
3. Preliminary clinical data indicate a lasting (> 12 months) therapeutic effect. Nevertheless the definitive future role of transrectal HIFU as a minimally invasive treatment option for BPH can only be established in a prospective, randornised phase III-trial against TUR/P, which is planned to start at the end of 1994.
Presently the HIFU-procedure is undergoing significant improvements at various levels. Firstly, the optimal anaesthetic protocol still needs to be defined. The majority of patients have been treated either under general or spinal anaesthesia. At the University of Indiana, 9/10 patients were successfully treated with i.v. sedation using propofol and fentanyl (6) . Patients were operated on as out-patients with no anaestethic recovery room time. At our institute we presently use a highly selective low spinal block, allowing patients to stand up as early as three hours post-treatment. Furthermore, the possibility of a prostatic block as an anaesthetic regimen is currently being evaluated. Secondly, the impact of the intraprostatic lesion volume on the clinical outcome is currently determined: by increasing the site intensity from 1680 WI em-up to 2200 WI cm-, a 500% increased intraprostatic lesion volume, as compared to the original protocol, can be obtained (15) .
Although we have demonstrated the clinical efficacy of HIFU in patients with symptomatic BPH, the major-implications for HIFU lies in the field of oncology. HIFU applied transcutaneously or through natural body cavities (e.g. transrectal, transvaginal) has the power to destroy any type of solid organ tumour accessible for ultrasound, as recently shown in various experimental settings (2, (16) (17) (18) (19) (20) . Recent data indicate that HIFU treatment significantlyprolongs survival in animals with liver tumours (2, (18) (19) (20) . Moreover, promising experimental data exist on the possibility of combining HIFU treatment with chemotherapy (17) .
One of the chief apprehensions until recently was a possible impact of HIFU on major blood vessels such as the aorta or the vena cava inferior. Yang et al. (19) have meanwhile demonstrated that neither of these vessels are significantly damaged even when focused directly, presumably owing to the mutual effect of short duty cycles and temperature regulation by the blood flow. HIFU could therefore be safely applied to retroperitoneal lymph nodes, central liver cancers or metastases as well as local recurrences after tumour nephrectomies. The aiming accuracy is another issue. Ultrasound guidance allows satisfactory identification of the treatment zone in the case of BPH due to the anatomy, the transrectal approach and the visualisation of the urethra and bladder neck with the aid of a urethral catheter. When it comes to treatment of deeper structures, e.g. retroperitoneal lymph nodes or central liver tumours as well as lesions which are difficultto identify with ultrasound, this imaging system is inadequate. A solution to this problem is HIFU guidance by MRI, which in animal studies .has already yielded encouraging results (21) .
Hence, the ultimate objective to be envisaged for clinical HIFU is non-invasive, transcutaneous, MRI-or ultrasound guided anticancer treatment use for both curative and palliative purposes.
